In VivoAs biosimilars flood into the wet age-related macular degeneration (AMD) market, they are reshaping the competitive landscape that was long dominated by anti-vascular endothelial growth factor (VEGF)
ScripTwo and a half months after its first US Food and Drug Administration approval for Incyte Corp.-partnered Niktimvo (axatilimab-csfr) in chronic graft-versus-host disease (GVHD), Syndax Pharmaceuticals
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lilly The Latest Pharma Company To Sign
ScripIn the more than six years since the US Food and Drug Administration approved Novartis AG ’s Kymriah (tisagenlecleucel) and Kite Pharma’s – now part of Gilead Sciences, Inc. – Yescarta (axicabtagen